Evidence map›Paper›PMID 21179163›Full record

ArticleNature2010

Driving the cell cycle with a minimal CDK control network.

Damien Coudreuse, Paul Nurse

Registry-linked trialAbstract read
PubMed Publisher
In one paragraph

Article in Nature, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04920708 (Randomised Open-label Phase II Study of Induction Standard of Care Fulvestrant and CDK4/6 Inhibition With the Addition of Ipatasertib in Metastatic ER+/HER2- Breast Cancer Patients Without ctDNA Suppression), which is not on this map. Cited by 224 papers.

0numbers the graph read from it
0cells of the map it votes in
224citing papers in PubMed
12.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04920708 phase2active not recruitingnot on this mapstarted 2022, after this paper: background citation

Randomised Open-label Phase II Study of Induction Standard of Care Fulvestrant and CDK4/6 Inhibition With the Addition of Ipatasertib in Metastatic ER+/HER2- Breast Cancer Patients Without ctDNA Suppression

TypeinterventionalSponsorRoyal Marsden NHS Foundation TrustRan2022 to 2027Enrolled57ConditionsMetastatic Breast Cancer, ER+ Breast Cancer, Advanced Breast CancerArmsIpatasertib 300mg, Fulvestrant 500g, Palbociclib 75mg-125mg, CDK4/6 Inhibitor
3 · Its place in the literature

Who cites it

224 citing papers in PubMed, 394 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Decoding Cdk1 control: from mitotic thresholds to meiotic specificity.Chromosome research : an international journal on the molecular, supramolecular and evolutionary aspects of chromosome biology · 2026
    Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. A bittersweet relationship between the cell cycle, circadian clock, and diurnal fluctuations in taste.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  13. Article
  14. Review
  15. Circadian Control of Protein Synthesis.BioEssays : news and reviews in molecular, cellular and developmental biology · 2025
    Review
  16. Article
  17. Article
  18. A concise guide to fluorescent cell cycle reporters for live-cell imaging.Frontiers in cell and developmental biology · 2025
    Review
  19. Review
  20. Article

164 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Damien CoudreuseLaboratory of Yeast Genetics and Cell Biology, The Rockefeller University, 1230 York Avenue, New York, New York 10065, USA. dcoudreuse@rockefeller.edu
Paul Nurse
Rockefeller University · US

Funding

Wellcome Trust 093917
6 · The paper itself

Abstract

Control of eukaryotic cell proliferation involves an extended regulatory network, the complexity of which has made it difficult to understand the basic principles of the cell cycle. To investigate the core engine of the mitotic cycle we have generated a minimal control network in fission yeast that efficiently sustains cellular reproduction. Here we demonstrate that orderly progression through the major events of the cell cycle can be driven by oscillation of an engineered monomolecular cyclin-dependent protein kinase (CDK) module lacking much of the canonical regulation. We show further that the CDK oscillator acts as the primary organizer of the cell cycle, imposing timing and directionality to a system of two CDK activity thresholds that define independent cell cycle phases. We propose that this simple core architecture forms the basic control of the eukaryotic cell cycle.

Indexed as

Biological ClocksCell CycleCell ProliferationCyclin-Dependent KinasesDNASchizosaccharomycesSchizosaccharomyces pombe ProteinsTime FactorsCyclin-Dependent KinasesDNASchizosaccharomyces pombe Proteins

Identifiers

PMID21179163
OpenAlexW2040091286

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.